KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer

Noelle L Cutter

KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer

Biology, Chemistry, Environmental Studies

Producción científica: Web publication/site

Resumen

Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1–enriched tumors experienced longer progression-free survival with the anti–PD-1 inhibitor.

Idioma original	American English
Estado	Published - may 3 2021

Disciplines

Life Sciences
Medicine and Health Sciences

Otros archivos y enlaces

Link to publication

Citar esto

@misc{549d612d0f00465396901a3122d09a61,

title = "KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer",

abstract = " Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1–enriched tumors experienced longer progression-free survival with the anti–PD-1 inhibitor.",

author = "Cutter, \{Noelle L\}",

note = "By: Noelle Cutter, PhD Posted: Monday, May 3, 2021 Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1-enriched tumors experienced longer progression-free survival with the anti-PD-1 inhibitor.",

year = "2021",

month = may,

day = "3",

language = "American English",

}

TY - ADVS

T1 - KEYNOTE-119: Pembrolizumab Versus Chemotherapy in Triple-Negative Breast Cancer

AU - Cutter, Noelle L

N1 - By: Noelle Cutter, PhD Posted: Monday, May 3, 2021 Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1-enriched tumors experienced longer progression-free survival with the anti-PD-1 inhibitor.

PY - 2021/5/3

Y1 - 2021/5/3

N2 - Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1–enriched tumors experienced longer progression-free survival with the anti–PD-1 inhibitor.

AB - Based on the phase III KEYNOTE-119 trial, published in The Lancet Oncology, pembrolizumab monotherapy versus single-drug chemotherapy for patients with previously treated metastatic triple-negative breast cancer did not significantly improve overall survival. However, patients with PD-L1–enriched tumors experienced longer progression-free survival with the anti–PD-1 inhibitor.

UR - https://jnccn360.org/breast/medical-literature/keynote-119-pembrolizumab-versus-chemotherapy-in-triple-negative-breast-cancer/

M3 - Web publication/site

ER -